Multiple Rare Disease Advocacy Groups Rank Horizon Therapeutics First in Corporate Reputation
Results based on a 2022 global PatientView survey.
Horizon Therapeutics plc revealed its ranking of first in overall corporate reputation among rare disease patient groups around the world who were familiar with the company. According to PatientView’s 2022 global Corporate Reputation of Pharma survey, Horizon ranked first in 10 of 14 indicators including patient centricity, patient information, integrity, access to medicines, relationships, and services. The survey included 426 patient groups who analyzed 34 pharma and biotech organizations.
“We are honored by the feedback that rare disease patient advocacy groups provided within the PatientView report,” said Matt Flesch, VP, patient advocacy, product communications, Horizon. “Our approach to patient advocacy is to participate, listen and learn, knowing that rare disease patient groups are usually the main catalyst for progress, driving awareness and education, building community, and advancing research toward treatments and cures. From the programs that we support to the initiatives that we create; our belief is that meaningful and appropriate collaboration with patient advocacy groups is core to all our work at Horizon.”
Reference: Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups. BusinessWire. August 23, 2023. Accessed August 24, 2023. https://www.businesswire.com/news/home/20230823744270/en/Horizon-Therapeutics-plc-Ranks-First-in-Overall-Corporate-Reputation-by-Rare-Disease-Patient-Advocacy-Groups
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
